Abstracts tagged "methotrexate (MTX)"

Abstract Number: 1306 • 2012 ACR/ARHP Annual Meeting
How well Do Patients with Rheumatoid and Psoriatic Arthritis Tolerate Methotrexate? A Retrospective Review of Discontinuation Data From a Large UK Cohort
Calum T. Goudie¹, John D. Fitzpatrick¹, Anshuman P. Malaviya² and Andrew J. Ostor², ¹University of Cambridge Medical School, Cambridge, United Kingdom, ²Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom
Background/Purpose: Due to its efficacy and safety, methotrexate (MTX) has become the first-line disease-modifying drug for rheumatoid (RA) and psoriatic arthritis (PsA). Although deemed safe,…
Abstract Number: 2171 • 2012 ACR/ARHP Annual Meeting
Comparative Efficacy of Biologics As Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Conventional Dmards: A Network Meta-Analysis
Felicity Buckley¹, Axel Finckh², Thomas W. Huizinga³, Fred Dejonckheere⁴ and Jeroen P. Jansen¹, ¹MAPI Consultancy, Boston, MA, ²Rhumatology, University Hospital of Geneva, Geneva, Switzerland, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: A number of meta-analyses compare the efficacy of biologics for rheumatoid arthritis (RA). However, systematic reviews comparing the efficacy of biologics as monotherapy versus…
Abstract Number: 1240 • 2012 ACR/ARHP Annual Meeting
Serum Anti-Müllerian Hormone Can Be Used to Determine Ovarian Reserve in Women with Rheumatoid Arthritis
Jenny Brouwer¹, Johanna M.W. Hazes², Joop S.E. Laven³, Izaäk Schipper³ and Radboud J.E.M. Dolhain⁴, ¹Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, ²Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Obstetrics & Gynaecology, division of Reproductive Medicine, Erasmus Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Planning of pregnancy is important in women with rheumatoid arthritis (RA). It is preferred to start a pregnancy after adjustment of medication and when…
Abstract Number: 2158 • 2012 ACR/ARHP Annual Meeting
Baseline Folate Related Biomarkers in Serum and erythrocytes Are Not Associated with Methotrexate Response and Adverse Events in Rheumatoid Arthritis
Maurits C.F.J. De Rotte¹, Saskia M.F. Pluijm², Maja Bulatovic³, Johanna M.W. Hazes⁴ and Robert De Jonge¹, ¹Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, ²Public Health, Erasmus Medical center, Rotterdam, Netherlands, ³Department of Paediatric Immunology, University Medical Centre Utrecht, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands
Background/Purpose: Methotrexate (MTX) is the most commonly used drug in rheumatoid arthritis (RA). 30% of patients fail to respond to the drug or suffer from…
Abstract Number: 562 • 2012 ACR/ARHP Annual Meeting
Prevalence and Predictors of Significant Liver Fibrosis in Methotrexate Treated Rheumatoid and Psoriatic Arthritis Patients Using Transient Elastography (fibroscan)
WC Chan¹, ML Yip² and CK Loo¹, ¹Division of Gastroenterology and Hepatology, Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong, ²Division of Rheumatology, Department of Medicine, Kwong Wah Hospital, Kowloon, Hong Kong
Background/Purpose: Methotrexate ( MTX ) is an anchor drug in the treatment of Rheumatoid ( RA ) and Psoriatic arthritis ( PSA )and is the…
Abstract Number: 2125 • 2012 ACR/ARHP Annual Meeting
Response to Methotrexate Plus Prednisone in Camera II Using a Multi-Biomarker Disease Activity (Vectra^TMDA) Test and DAS28-ESR
J.W.J. Bijlsma¹, M. Verhoef-Jurgens², M.F. Bakker¹, J.W.G. Jacobs¹, F.P.J.G. Lafeber¹, P.M.J. Welsing³, G. Cavet⁴, D. Chernoff⁴ and D.J. Haney⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology & Clinical Immunology, F02.127, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Crescendo Bioscience, Inc., South San Francisco, CA
Background/Purpose: The CAMERA II study (Computer Assisted Management in Early RA) demonstrated that the addition of prednisone to a MTX-based tight control strategy increased effectiveness…
Abstract Number: 566 • 2012 ACR/ARHP Annual Meeting
Effect of TNF Antagonists On Radiographic Progression in Psoriatic Arthritis: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Radjiv Goulabchand¹, Gael Mouterde¹, Cédric Lukas², Thomas Barnetche³, Jacques Morel¹ and Bernard Combe¹, ¹Rheumatology, Montpellier 1 University, Lapeyronie Hospital, Montpellier, France, ²Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ³Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France
Background/Purpose: Psoriatic arthritis (PsA) can cause important structural damages which can lead to disability. TNF antagonists have shown their clinical efficacy in PsA, but only…
Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir¹, Marie Holmqvist², Johan Askling³, Lars Alfredsson⁴ and Lars Klareskog⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…
Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Varun Dhir¹, Mandeep Singla², Palvi Goyal², Vinay Sagar², Aman Sharma¹ and Shefali K. Sharma², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…
Abstract Number: 2074 • 2012 ACR/ARHP Annual Meeting
Combined Effects of a c-Fos/AP-1 Inhibitor T-5224 and Methotrexate On Collagen-Induced Arthritis in Mice
Tomomi Date¹, Yukihiko Aikawa¹, Tetsuya Yamamoto¹, Hirokazu Narita¹, Shuichi Hirono² and Shunichi Shiozawa³, ¹Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, ²Department of Pharmaceutical Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan, ³Department of Medicine & Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Activator protein-1 (AP-1) is an important transcription factor for cytokine production and joint destruction in rheumatoid arthritis (RA), and a potential target for the…
Abstract Number: 455 • 2012 ACR/ARHP Annual Meeting
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Keisuke Izumi¹, Yuko Kaneko², Hidekata Yasuoka³, Noriyuki Seta⁴, Hideto Kameda⁵, Masataka Kuwana⁵ and Tsutomu Takeuchi⁶, ¹Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ²Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Keio university, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: To explore the benefit of concomitant use of methotrexate (MTX) for the effectiveness of TCZ in rheumatoid arthritis (RA) patients in daily clinical practice.…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…
Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting
Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Heather Jones¹, Annette Szumski² and Andrew S. Koenig³, ¹Pfizer Inc., Collegeville, PA, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…
Abstract Number: 1822 • 2012 ACR/ARHP Annual Meeting
Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans
Gabriela Schmajuk¹, Yinghui Miao², Jinoos Yazdany³, Mary Margaretten⁴ and Michael Steinman², ¹Rheumatology, UCSF / San Francisco VA Medical Center, San Francisco, CA, ²Division of Geriatrics, UCSF, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The National Quality Forum recently endorsed a controversial quality measure that assesses liver toxicity monitoring for patients receiving oral methotrexate (MTX). Using national data…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].